• +1-646-491-9876
    • +91-20-67278686

    Search

    Impetigo - Pipeline Review, H2 2016

    Impetigo - Pipeline Review, H2 2016

    • Report Code ID: RW0001492630
    • Category Pharmaceuticals
    • No. of Pages 45
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2016, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.

    Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Impetigo.

    Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Impetigo Overview 6
    Therapeutics Development 7
    Pipeline Products for Impetigo - Overview 7
    Pipeline Products for Impetigo - Comparative Analysis 8
    Impetigo - Therapeutics under Development by Companies 9
    Impetigo - Therapeutics under Investigation by Universities/Institutes 10
    Impetigo - Pipeline Products Glance 11
    Late Stage Products 11
    Clinical Stage Products 12
    Early Stage Products 13
    Impetigo - Products under Development by Companies 14
    Impetigo - Products under Investigation by Universities/Institutes 15
    Impetigo - Companies Involved in Therapeutics Development 16
    Foamix Pharmaceuticals Ltd 16
    Laboratories Ojer Pharma SL 17
    Lytix Biopharma AS 18
    Toyama Chemical Co Ltd 19
    Impetigo - Therapeutics Assessment 20
    Assessment by Monotherapy Products 20
    Assessment by Target 21
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Drug Profiles 29
    FMX-102 - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    LTX-109 - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    mupirocin - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    ozenoxacin - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Synthetic Peptides for Infectious Disease - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    Impetigo - Dormant Projects 36
    Impetigo - Discontinued Products 37
    Impetigo - Product Development Milestones 38
    Featured News & Press Releases 38
    Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada 38
    Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA 38
    Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment 39
    Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer 39
    Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo 40
    Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study 41
    Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin 41
    Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions 42
    Appendix 44
    Methodology 44
    Coverage 44
    Secondary Research 44
    Primary Research 44
    Expert Panel Validation 44
    Contact Us 44
    Disclaimer 45

    List of Tables

    Number of Products under Development for Impetigo, H2 2016 7
    Number of Products under Development for Impetigo - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Number of Products under Investigation by Universities/Institutes, H2 2016 10
    Comparative Analysis by Late Stage Development, H2 2016 11
    Comparative Analysis by Clinical Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Development, H2 2016 13
    Products under Development by Companies, H2 2016 14
    Products under Investigation by Universities/Institutes, H2 2016 15
    Impetigo - Pipeline by Foamix Pharmaceuticals Ltd, H2 2016 16
    Impetigo - Pipeline by Laboratories Ojer Pharma SL, H2 2016 17
    Impetigo - Pipeline by Lytix Biopharma AS, H2 2016 18
    Impetigo - Pipeline by Toyama Chemical Co Ltd, H2 2016 19
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Stage and Target, H2 2016 22
    Number of Products by Stage and Mechanism of Action, H2 2016 24
    Number of Products by Stage and Route of Administration, H2 2016 26
    Number of Products by Stage and Molecule Type, H2 2016 28
    Impetigo - Dormant Projects, H2 2016 36
    Impetigo - Discontinued Products, H2 2016 37

    List of Figures

    Number of Products under Development for Impetigo, H2 2016 7
    Number of Products under Development for Impetigo - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 11
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Targets, H2 2016 21
    Number of Products by Stage and Top 10 Targets, H2 2016 21
    Number of Products by Mechanism of Actions, H2 2016 23
    Number of Products by Stage and Mechanism of Actions, H2 2016 23
    Number of Products by Routes of Administration, H2 2016 25
    Number of Products by Stage and Routes of Administration, H2 2016 25
    Number of Products by Molecule Types, H2 2016 27
    Number of Products by Stage and Molecule Types, H2 2016 27
    Foamix Pharmaceuticals Ltd
    Laboratories Ojer Pharma SL
    Lytix Biopharma AS
    Toyama Chemical Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments